The short latency and high incidence of TP53mut following CAR‐T therapy were comparable between LPD and MM cases treated with CD19‐ and BCMA‐directed constructs—suggesting a potential mechanistic link between CAR‐T therapy and the subsequent MN. The gene discussed is CD19; the disease is Miyoshi myopathy.